Interferon-inhibiting activities in sera of patients with lung cancer.

Karmaniolas, K; Tsantakis, G; Havredaki, M

Karmaniolas, K; Tsantakis, G; Havredaki, M.

Afiliación

Karmaniolas K; 3rd Department of Internal Medicine, NIMTS Hospital, Petraki, Athens, Greece.

Arch Immunol Ther Exp (Warsz) ; 45(1): 61-5, 1997.

Article en En | MEDLINE | ID: mdl-9090442

RESUMEN

A differential pattern of sera exhibiting interferon-inhibiting activity in cases of histologically confirmed lung cancer patients have been observed. The sera distribution was dependent on the clinical entity and the cell line specificity used measuring IFN-inhibition. Although either small cell lung cancer (SCLC) or non small cell lung cancer (NSCLC) sera exhibiting in a high percentage (80 and 75% respectively) such an activity, in any of the 3 lines tested, the ratio of sera exerting inhibition in each cell line was different. Such cell specific systems could be of prognostic/predicting value for effective therapeutic schedules of specific clinical entities.

Asunto(s)

Antivirales/sangre; Interferones/antagonistas & inhibidores; Neoplasias Pulmonares/sangre; Anciano; Carcinoma de Pulmón de Células no Pequeñas/sangre; Carcinoma de Pulmón de Células no Pequeñas/metabolismo; Carcinoma de Células Pequeñas/sangre; Carcinoma de Células Pequeñas/metabolismo; Efecto Citopatogénico Viral/efectos de los fármacos; Femenino; Humanos; Interferón alfa-2; Interferón-alfa/antagonistas & inhibidores; Masculino; Proteínas Recombinantes; Células Tumorales Cultivadas

Buscar en Google

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Antivirales / Interferones / Neoplasias Pulmonares Límite: Aged / Female / Humans / Male Idioma: En Revista: Arch Immunol Ther Exp (Warsz) Año: 1997 Tipo del documento: Article País de afiliación: Grecia Pais de publicación: Suiza

Buscar en Google

Añadir a Mi BVS

Imprimir

XML

PubMed Links